Infant RSV Immunity Study

Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\6-9 months) in infancy.

Inclusion Criteria: Birthing parent/child pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital. Exclusion Criteria: Severe pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \< 35 weeks of gestation, or with chronic medical conditions).